1[1]Matchar DB,Samsa GP,Liu S. Cost - effectiveness of antiplatelet agents in secondary stroke prevention:the limits of certainty. Value Health ,2005,8 ( 5 ) :572 ～ 580
3[3]Multicentre Acute Stroke Trial Italy Group ( MAST - Ⅰ). Randomized controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet, 1995,346:1509 ～ 1514
4[4]International Stroke Trial Collaborative Group (IST). A randomized trial of aspirin, subcutaneous heparin both,or neither among 19 435 patients with acute alchemic stroke. Lancet, 1997,349:1569 ～ 1581
5[5]Chinese Acute Stroke Trial Collaborative Group (CAST). Randomized placebo 2 controlled trial of early aspirin use in 20000 patients with acute ischemic stroke. Lancet, 1997,349:1641 ～ 1649
6[6]Hillarp A,Palmqvist B,Lethagen S,et al. Mutation within the cyclooxygenase - 1 gene in aspirin non - responders with recurrence of stroke. Thromb Res,2003,112:275 ～ 283
7[7]Kong DF. Aspirin in cardiovascular disorders:what is the optimum dose? Am Cardiovasc Drug,2004,4:151 ～ 158
8[8]Jamieson DG, Parekh A, Ezekowitz MD. Review of antiplatelet therapy in secondary prevention of cerebrovascular events:a need for direct comparisons between antiplatelet agents. J Cardiovasc Pharmacol Ther. 2005,10( 3 ): 153 ～ 161
9[9]Urbano LA,Bogousslavsky J. Antiplatelet drugs in ischemic stroke prevention :from monotherapy to combined treatment. Cerebrovasc Dis ,2004,17 ( Suppl. ): S74 ～ S80
10[10]Patscheke H. Platelet aggregation disorders. Hamostaseologie,2003,23:181 ～ 185
